Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30410027.
- Also identified by DOI 10.1038/s41467-018-06920-9 and PMC identifier 6224563.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, r<sub>g</sub> = 0.77 (P = 2.6 × 10<sup>-11</sup>), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10<sup>-55</sup>). These results shed a light on the genetic background of BPH/LUTS and its substantial influence on PSA levels.
Medical subject headings
- Genome-Wide Association Study
- Prostate-Specific Antigen
- Prostatic Hyperplasia